title: [Eptifibatide (Integrilin)].
abstract: Eptifibatide (Integrilin) is a specific blocker of the glycoprotein IIb/IIIa receptor and an effective inhibitor of platelet aggregation. It reduces coronary events in patients with acute coronary syndromes and no elevation in the electrocardiographic ST segment. The present summary discusses the indications for the use of eptifibatide/Integrilin based on recent clinical trials and cost-benefit analyses.
authors.affiliation: H:S Rigshospitalet, Hjertecentret, medicinsk afdeling B.
authors.forename: L
authors.initials: L
authors.lastname: Holmvang
authors.forename: P
authors.initials: P
authors.lastname: Grande
mesh_terms: D000077542:Eptifibatide; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D010455:Peptides / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000187:drug effects
chemical_list: D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077542:Eptifibatide
vernacular_title: Eptifibatide (Integrilin).